Eisai Plans More Global Cost Cuts In Wake Of Loss Of Aricept Patent
This article was originally published in PharmAsia News
Executive Summary
Eisai says it plans additional cost cuts by the end of the current fiscal year March, 2013, as a result of the patent-expiration of Alzheimer’s disease drug Aricept (donepezil).